Acclarent Whistleblower Says Device Off-Label Marketing Too Risky
Executive Summary
The former device industry sales rep behind the Acclarent off-label marketing case argues against any off-label marketing of devices, saying the 510(k) process and financial motives make it too risky.
You may also be interested in...
US FDA Hears Competing Messages On Off-Label Communications
Over the course of a two-day meeting at FDA headquarters, the agency heard from the medtech industry, which argued for expanding rights to off-label promotion, and consumer groups that worry about the possible impact on the public health. The meeting is intended to inform FDA's comprehensive review of its regulations and policies governing firms' communications about unapproved uses of approved/cleared products.
Acclarent Execs Move To Appeal Off-Label Conviction
Attorneys for former Acclarent executives William Facteau and Patrick Fabian have filed a request that their convictions on off-label marketing charges either be set aside or that they be granted a new trial, citing other recent off-label trials and misconduct by the government.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.